LifeMD (NASDAQ:LFMD) Shares Up 13.3% - Time to Buy?

Key Points

• LifeMD's stock price rose 13.3% to $11.26 amidst a trading volume decrease of 52% from its average.
• Analysts are divided on the stock, with two rating it a hold and five giving a buy rating, while the average price target is $13.86.
• Insider trading has seen significant activity, with the CEO selling 25,000 shares and insiders collectively selling about 275,000 shares in the last 90 days.

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) shot up 13.3% during trading on Monday . The company traded as high as $11.48 and last traded at $11.26. 714,821 shares changed hands during trading, a decline of 52% from the average session volume of 1,483,000 shares. The stock had previously closed at $9.94.

Analysts Set New Price Targets

LFMD has been the topic of several recent research reports. BTIG Research lifted their price target on LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a research note on Wednesday, June 18th. KeyCorp lowered their price objective on shares of LifeMD from $14.00 to $12.00 and set an "overweight" rating on the stock in a report on Wednesday. HC Wainwright reduced their target price on shares of LifeMD from $14.00 to $13.00 and set a "buy" rating for the company in a report on Thursday. Wall Street Zen lowered shares of LifeMD from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, Lake Street Capital reduced their price objective on shares of LifeMD from $18.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, LifeMD currently has an average rating of "Moderate Buy" and an average target price of $12.86.

LifeMD Trading Up 2.8%

The business has a 50 day moving average of $11.97 and a two-hundred day moving average of $8.46. The company has a current ratio of 0.77, a quick ratio of 0.77 and a debt-to-equity ratio of 9.21. The firm has a market cap of $308.83 million, a P/E ratio of -32.19 and a beta of 1.72.

LifeMD (NASDAQ:LFMD - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.05. The company had revenue of $65.70 million for the quarter, compared to analyst estimates of $62.47 million. Analysts predict that LifeMD, Inc. will post -0.56 earnings per share for the current year.

Insider Buying and Selling

In other LifeMD news, insider Eric Harold Yecies sold 15,000 shares of LifeMD stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $12.25, for a total value of $183,750.00. Following the transaction, the insider owned 16,100 shares in the company, valued at $197,225. The trade was a 48.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Justin Schreiber sold 25,000 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $13.38, for a total transaction of $334,500.00. Following the transaction, the chief executive officer owned 2,500,721 shares of the company's stock, valued at approximately $33,459,646.98. This represents a 0.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 275,000 shares of company stock worth $3,564,550 in the last quarter. Insiders own 18.40% of the company's stock.

Institutional Investors Weigh In On LifeMD

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its holdings in LifeMD by 148.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company's stock worth $50,000 after acquiring an additional 2,185 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in LifeMD by 1,004.9% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,171 shares of the company's stock valued at $70,000 after buying an additional 4,703 shares during the period. GAMMA Investing LLC bought a new stake in LifeMD during the first quarter valued at $35,000. CWM LLC boosted its position in LifeMD by 17.5% during the first quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after acquiring an additional 1,351 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft acquired a new stake in LifeMD during the 2nd quarter worth about $136,000. Institutional investors own 35.52% of the company's stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.